SG162605A1 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
SG162605A1
SG162605A1 SG200501782-7A SG2005017827A SG162605A1 SG 162605 A1 SG162605 A1 SG 162605A1 SG 2005017827 A SG2005017827 A SG 2005017827A SG 162605 A1 SG162605 A1 SG 162605A1
Authority
SG
Singapore
Prior art keywords
pharmaceutical compositions
pharmaceutically acceptable
valsartan
bioavailable
hydrate
Prior art date
Application number
SG200501782-7A
Other languages
English (en)
Inventor
Sabina Maria Ganter
Robert Frank Wagner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG162605A1 publication Critical patent/SG162605A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG200501782-7A 2000-06-22 2001-06-20 Pharmaceutical compositions SG162605A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
SG162605A1 true SG162605A1 (en) 2010-07-29

Family

ID=24400655

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200501782-7A SG162605A1 (en) 2000-06-22 2001-06-20 Pharmaceutical compositions

Country Status (21)

Country Link
EP (2) EP1296677A2 (xx)
JP (3) JP2003535895A (xx)
KR (2) KR100659644B1 (xx)
CN (2) CN100450478C (xx)
AU (2) AU8576801A (xx)
BR (1) BR0111868A (xx)
CA (1) CA2411882C (xx)
CZ (1) CZ20024180A3 (xx)
EC (1) ECSP024389A (xx)
HK (2) HK1052868A1 (xx)
HU (1) HUP0301390A3 (xx)
IL (2) IL153428A0 (xx)
MX (1) MXPA02012683A (xx)
NO (1) NO20026123L (xx)
NZ (2) NZ540748A (xx)
PL (1) PL358290A1 (xx)
RU (1) RU2333757C2 (xx)
SG (1) SG162605A1 (xx)
SK (1) SK18062002A3 (xx)
WO (1) WO2001097805A2 (xx)
ZA (1) ZA200210359B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200200764T2 (tr) * 1998-12-23 2002-07-22 Novartis Ag At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı
MXPA04006917A (es) * 2002-01-17 2004-12-06 Novartis Ag Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra.
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
WO2005013964A1 (ja) 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
CA2592091A1 (en) 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
RU2487710C2 (ru) 2007-10-09 2013-07-20 Новартис Аг Фармацевтическая композиция валсартана
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049394A2 (en) * 1996-06-27 1997-12-31 Novartis Ag Sold oral dosage forms of valsartan
WO2000038676A1 (en) * 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
WO2001076573A2 (en) * 2000-04-12 2001-10-18 Novartis Ag Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000024I1 (de) * 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
AU1850695A (en) * 1994-03-17 1995-10-03 Novartis Ag Treatment of diabetic nephropathy with valsartan
DE69624253T2 (de) * 1995-10-06 2003-08-07 Novartis Ag Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
JP4369994B2 (ja) * 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト アポトーシスの刺激のためのａｔ▲下１▼レセプターアンタゴニスト
JP3391801B2 (ja) * 1996-05-20 2003-03-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 向上した生物学的利用性を有する抗菌性組成物
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049394A2 (en) * 1996-06-27 1997-12-31 Novartis Ag Sold oral dosage forms of valsartan
WO2000038676A1 (en) * 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
WO2001076573A2 (en) * 2000-04-12 2001-10-18 Novartis Ag Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups

Also Published As

Publication number Publication date
RU2333757C2 (ru) 2008-09-20
NO20026123D0 (no) 2002-12-19
HK1052868A1 (zh) 2003-10-03
CA2411882C (en) 2011-09-06
CN100450478C (zh) 2009-01-14
ECSP024389A (es) 2003-02-06
AU2001285768B2 (en) 2005-03-10
HUP0301390A3 (en) 2005-04-28
EP2072049A3 (en) 2009-12-30
CN1221256C (zh) 2005-10-05
CN1679551A (zh) 2005-10-12
WO2001097805A2 (en) 2001-12-27
CA2411882A1 (en) 2001-12-27
CN1437469A (zh) 2003-08-20
EP2072049A2 (en) 2009-06-24
ZA200210359B (en) 2003-11-13
EP1296677A2 (en) 2003-04-02
NO20026123L (no) 2003-02-18
KR20030019450A (ko) 2003-03-06
SK18062002A3 (sk) 2003-07-01
HK1083452A1 (en) 2006-07-07
PL358290A1 (en) 2004-08-09
CZ20024180A3 (cs) 2003-04-16
JP2007091758A (ja) 2007-04-12
BR0111868A (pt) 2003-07-01
JP2012211200A (ja) 2012-11-01
JP2003535895A (ja) 2003-12-02
NZ522953A (en) 2005-10-28
KR100525341B1 (ko) 2005-11-02
MXPA02012683A (es) 2003-04-25
NZ540748A (en) 2007-04-27
KR20050085978A (ko) 2005-08-29
WO2001097805A3 (en) 2002-08-29
IL153428A (en) 2013-12-31
KR100659644B1 (ko) 2006-12-21
IL153428A0 (en) 2003-07-06
AU8576801A (en) 2002-01-02
HUP0301390A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
SG162605A1 (en) Pharmaceutical compositions
CA2378469A1 (en) An oral solid composition comprising carbidopa, levodopa and entacapone
CA2427815A1 (en) Controlled release hydrocodone formulations
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
IL150696A0 (en) Pharmaceutical compositions containing benzimidazole derivatives and processes for the manufacture thereof
EP1337249A4 (en) COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE COMPOUNDS
WO2001042219A3 (en) Novel substituted phenanthridinones and methods of use thereof
PL342988A1 (en) Novel galenic formulations of meloxicam for oral administration
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
DE69413237D1 (en) Plättchenaggregationsinhibitoren
BG105436A (en) Pharmaceutical compositions comprising entacapone or nitecapone as well as a cross-linked cellulpse derivative
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HUP0204080A3 (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
HUP0105426A3 (en) Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems and pharmaceutical compositions thereof
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative
AU2382997A (en) Diclofenac/gamma-cyclodextrin inclusion compounds
WO2002011740A3 (en) 'slow release' pharmaceutical compositions comprising lithium carbonate
WO2000064427A3 (en) Lamivudine containing pharmaceutical formulation
HUP0401912A3 (en) Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them
HUP0200993A3 (en) Thio-oxindole derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them